Nootropic Peptides is an independent educational reference site covering research peptides relevant to cognitive enhancement, neuroprotection, mood, focus, and brain health. The site catalogues mechanism of action, published research, safety profile, and UK and EU regulatory status for each compound — written in a neutral, evidence-based tone, without therapeutic claims and without selling anything.

The peptides discussed here are research chemicals, not medicines. None are licensed for human use in the United Kingdom. The site exists because the existing online information landscape for these compounds is dominated by either marketing copy or speculation, and a neutral reference is genuinely useful for researchers, students, and informed readers who want to understand the actual state of the published literature.

Where the site links to commercial suppliers — explicitly, on each peptide page — it does so because researchers genuinely do need to source these compounds for laboratory work, and a clear pointer to known UK suppliers is more useful than pretending the question does not arise. Those links should be read as research-sourcing references, not as endorsements of human consumption.

How the site is structured

Each peptide profile follows the same template — quick-facts panel, biochemistry overview, discovery history, mechanism of action, researched benefits, theoretical dosing protocols, administration routes, safety profile, UK and EU regulatory context, clinical studies summary, FAQs, sourcing notes, and related peptides. The uniform structure means readers can compare across peptides quickly and can rely on finding the same kind of information in the same place.

Comparison pages, stack guides, and topic-level research summaries cover the cross-cutting questions — how does Semax differ from Selank, what does the BDNF-induction literature actually show, why is intranasal delivery the standard route in this research family.

Editorial process and update cadence

Every peptide profile carries a "last reviewed" date in its header. The default cadence is a quarterly audit — published research is checked, new studies are summarised, regulatory-status statements are reverified against current MHRA and EMA positions, and the last-reviewed date is bumped. High-profile updates (new clinical trial results, material regulatory changes, retractions in the literature) trigger immediate revisions outside the regular cadence.

We deliberately avoid auto-generated content and avoid republishing copy from supplier sites. Every page on this site is written from primary or peer-reviewed secondary sources by a human editor with the brief: write it as if the reader is a PhD student in pharmacology rather than a consumer.

Conflicts of interest and disclosure

This site links externally to two commercial peptide suppliers — PeptideAuthority.co.uk and PeptideBarn.co.uk — under "Sourcing for laboratory research" sections on each peptide page. Those links are not paid advertising and do not currently carry an affiliate commission. They are present because researchers do need a real-world answer to the "where do I get this for laboratory work" question, and named UK suppliers with traceable documentation are a meaningfully better answer than unverified offshore vendors.

If the commercial relationship changes — for instance, if these links become affiliate links — that disclosure will be added to every page that contains them. No content decision on this site (which peptides to cover, what to say about them, which studies to summarise) is influenced by any commercial relationship.

Reporting errors

If you spot a factual error — a misstated mechanism, a study referenced incorrectly, a regulatory claim that is out of date — please flag it. Corrections are made within a working week and the affected page's "last reviewed" date is bumped. We treat corrections as a feature of the site, not an embarrassment: the only way to maintain a credible reference is to fix the things that turn out to be wrong.